Kurzporträt
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Autologous Tumor Infiltrating Lymphocytes
100,0
%
| 0 | nan % | 1 | 100,0 % | - |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | nan % | 1 | 100,0 % | - |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 30.09.16 |
Director of Finance/CFO | 51 | 14.12.20 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 01.07.21 |
Chief Tech/Sci/R&D Officer | 51 | 18.07.19 | |
Igor Bilinsky
COO | Chief Operating Officer | 51 | 15.03.21 |
Merrill McPeak
BRD | Director/Board Member | 88 | 20.07.11 |
Sara Pellegrino
IRC | Investor Relations Contact | - | - |
Tracy Winton
HRO | Human Resources Officer | - | 01.04.20 |
Raj K. Puri
PRN | Corporate Officer/Principal | - | 01.03.22 |
Jim Ziegler
PRN | Corporate Officer/Principal | - | 01.02.20 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 20.07.11 |
Director/Board Member | 56 | 07.06.16 | |
Michael Weiser
BRD | Director/Board Member | 61 | 15.03.18 |
Wendy Yarno
BRD | Director/Board Member | 69 | 18.04.23 |
Ryan Maynard
BRD | Director/Board Member | 54 | 16.02.15 |
Iain Dukes
CHM | Chairman | 65 | 01.06.16 |
Director/Board Member | 52 | 10.06.19 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 0 | 2 842 158 | 0 | 0 | 92,59 % |
Aktie B | 0 | 194 | 0 | 0 | |
Aktie C | 1 | 279 832 722 | 259 105 707 ( 92,59 %) | 0 |
Unternehmenskontakt
Iovance Biotherapeutics, Inc.
825 Industrial Road Suite 400
94070, San Carlos
+650 260 7120
http://www.iovance.comSektor
% 1. Jan. | Kap. | |
---|---|---|
-27,90 % | 9,96 Mrd. | |
-4,81 % | 3,03 Mrd. | |
-14,73 % | 2,18 Mrd. | |
-14,39 % | 1,76 Mrd. | |
+70,99 % | 1,42 Mrd. | |
+23,17 % | 794 Mio. | |
-2,18 % | 756 Mio. | |
+3,18 % | 305 Mio. | |
+6,63 % | 208 Mio. |